Drug Profile
GTB 3650
Alternative Names: Anti-CD16-IL-15-anti-CD33 TriKE; GTB-3650; OXS-C3550; OXS-C3550 TriKELatest Information Update: 06 Dec 2023
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer GT Biopharma; University of Minnesota
- Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 15 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 04 Dec 2023 GT Biopharma files an IND application with the US FDA for Acute myeloid leukemia and Myelodysplastic syndrome
- 01 Nov 2023 GT Biopharma intends to file an IND application for phase I clinical trial in Acute Myeloid Leukaemia in USA, in the fourth quarter of 2023
- 01 Nov 2023 GT Biopharma plans a phase I trial in acute myeloid leukaemia in USA in 2024